IPCS Framework for Analyzing the Relevance of a Noncancer Mode of Action for Humans

REFERENCES

• Boobis A. R., Cohen S. M., Dellarco V., McGregor D., Meek M. E., Vickers C., Willcocks D., Farland W. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit. Rev. Toxicol 2006; 36: 781–792
   PubMed Web of Science ®Google Scholar
• Corley R. A., Meek M. E., Carney E. W. Mode of action: Oxalate crystal-induced renal tubule degeneration and glycolic acid-induced dysmorphogenesis—Renal and developmental effects of ethylene glycol. Crit. Rev. Toxicol 2005; 35: 691–702
   PubMed Web of Science ®Google Scholar
• Crofton K. M., Zoeller R. T. Mode of action: Neurotoxicity induced by thyroid hormone disruption during development—Hearing loss resulting from exposure to PHAHs. Crit. Rev. Toxicol 2005; 35: 757–769
   PubMed Web of Science ®Google Scholar
• Foster P. M. Mode of action: Impaired fetal Leydig cell function—Effects on male reproductive development produced by certain phthalate esters. Crit. Rev. Toxicol 2005; 35: 713–719
   PubMed Web of Science ®Google Scholar
• Hill A. B. The environment and disease: Association or causation?. Proc. R. Soc. Med. 1965; 58: 295–300
   PubMed Web of Science ®Google Scholar
• Holson J. F., Stump D. G., Pearce L. B., Watson R. E., DeSesso J. M. Mode of action: Yolk sac poisoning and impeded histiotrophic nutrition—HBOC-related congenital malformations. Crit. Rev. Toxicol 2005; 35: 739–745
   PubMed Web of Science ®Google Scholar
• Intergovernmental Forum on Chemical Safety. The International Conference on Chemical Safety—Final report. World Health Organization, GenevaSwitzerland 1994, http://www.who.int/ifcs/documents/forums/forum1/en/FI-report_en.pdf
   Google Scholar
• IPCS. Chemical-specific adjustment factors for interspecies differences and human variability: Guidance document for use of data in dose/concentration–response assessment. World Health Organization, International Programme on Chemical Safety, GenevaSwitzerland 2005, http://whqlibdoc.who.int/publications/2005/9241546786_eng.pdf Harmonization Project Document No. 2
   Google Scholar
• Kavlock R., Cummings A. Mode of action: Reduction of testosterone availability—Molinate-induced inhibition of spermatogenesis. Crit. Rev. Toxicol 2005a; 35: 685–690
   PubMed Web of Science ®Google Scholar
• Kavlock R., Cummings A. Mode of action: Inhibition of androgen receptor function—Vinclozolin-induced malformations in reproductive development. Crit. Rev. Toxicol 2005b; 35: 721–726
   PubMed Web of Science ®Google Scholar
• Meek M. E., Bucher J. R., Cohen S. M., Dellarco V., Hill R. N., Lehman-McKeeman L. D., Longfellow D. G., Pastoor T., Seed J., Patton D. E. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol 2003; 33: 591–653
   PubMed Web of Science ®Google Scholar
• Seed J., Carney E., Corley R., Crofton K., DeSesso J., Foster P., Kavlock R., Kimmel G., Klaunig J., Meek E., Preston J., Slikker W., Tabacova S., Williams G. Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit. Rev. Toxicol 2005; 35: 663–672
   Web of Science ®Google Scholar
• Slikker W., Jr., Andersen M. E., Bogdanffy M. S., Bus J. S., Cohen S. D., Conolly R. B., David R. M., Doerrer N. G., Dorman D. C., Gaylor D. W., Hattis D., Rogers J. M., Setzer R. W., Swenberg J. A., Wallace K. Dose-dependent transitions in mechanisms of toxicity. Toxicol. Appl. Pharmacol 2004; 201: 203–225
   PubMed Web of Science ®Google Scholar
• Slikker W., Jr., Xu Z. A., Levin E. D., Slotkin T. A. Mode of action: Disruption of brain cell replication, second messenger, and neurotransmitter systems during development leading to cognitive dysfunction—Developmental neurotoxicity of nicotine. Crit. Rev. Toxicol 2005; 35: 703–711
   PubMed Web of Science ®Google Scholar
• Sonich-Mullin C., Fielder R., Wiltse J., Baetcke K., Dempsey J., Fenner-Crisp P., Grant D., Hartley M., Knaap A., Kroese D., Mangelsdorf I., Meek E., Rice J., Younes M. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul. Toxicol. Pharmacol 2001; 34: 146–152
   PubMed Web of Science ®Google Scholar
• Tabacova S. Mode of action: Angiotensin-converting enzyme inhibition—Developmental effects associated with exposure to ACE inhibitors. Crit. Rev. Toxicol 2005; 35: 747–755
   PubMed Web of Science ®Google Scholar
• United Nations. Agenda 21: United Nations Conference on Environment and Development. United Nations Division for Sustainable Development, New York 1992, http://www.un.org/esa/sustdev/documents/agenda21/english/Agenda21.pdf
   Google Scholar
• UNEP. Plan of implementation of the World Summit on Sustainable Development. United Nations Environment Programme, New York 2002, http://www.un.org/esa/sustdev/documents/WSSD_POI_PD/English/WSSD_PlanImpl.pdf
   Google Scholar
• Weed D. L. Weight of evidence: A review of concept and methods. Risk Anal 2005; 25: 1545–1557
   PubMed Web of Science ®Google Scholar
• Wiltse J. Mode of action: Inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin—Developmental effects of valproic acid. Crit. Rev. Toxicol 2005; 35: 727–738
   PubMed Web of Science ®Google Scholar
• WHO. Strategic Approach to International Chemicals Management (SAICM). World Health Organization, GenevaSwitzerland 2006, http://www.who.int/ipcs/features/iccm_crp.pdf
   Google Scholar
• Zoeller R. T., Crofton K. M. Mode of action: Developmental thyroid hormone insufficiency—neurological abnormalities resulting from exposure to propylthiouracil. Crit. Rev. Toxicol 2005; 35: 771–781
   PubMed Web of Science ®Google Scholar
• Principles and practices for direct dosing of preweaning mammals in toxicity testing and research. A report of the ILSI Risk Science Institute Expert Working Group on Direct Dosing of Preweaning Mammals in Toxicity Testing, T. Zoetis, I. Walls. ILSI Press, Washington, DC 2003
   Google Scholar